{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:04:49Z","timestamp":1792087489375,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ihj.2025.02.007","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:55:44Z","timestamp":1740502544000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Factor XI and XII inhibitors\u2013Dawn of a new era"],"prefix":"10.1016","volume":"77","author":[{"given":"Chhabi","family":"Satpathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinath Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu Kumar","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2025.02.007_bib1","unstructured":"Becker RC. Fibrinolytic and Antithrombotic therapy - theory, Practice and Management. 1st ed. New York: Oxford university press; c2000. [Chapter 1], Historical Perspectives in homeostasis, thrombosis and fibrinolysis; pg. 1\u20137."},{"key":"10.1016\/j.ihj.2025.02.007_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1365-2141.1999.01689.x","article-title":"Coagulation history, oxford 1951\u201353","volume":"107","author":"Douglas","year":"1999","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ihj.2025.02.007_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J Anaesth"},{"issue":"5","key":"10.1016\/j.ihj.2025.02.007_bib4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/ALN.0b013e3181f22b5a","article-title":"Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution","volume":"113","author":"Bolliger","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ihj.2025.02.007_bib5","series-title":"Cell Surface GRP78, a New Paradigm in Signal Transduction Biology","first-page":"63","article-title":"Richard C. Austin. Cell surface GRP78: a novel regulator of tissue factor procoagulant activity","author":"Ali","year":"2018"},{"issue":"6","key":"10.1016\/j.ihj.2025.02.007_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1161\/ATVBAHA.118.311102","article-title":"Glycosaminoglycan neutralization in coagulation control","volume":"38","author":"Sobczak","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ihj.2025.02.007_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1603937","article-title":"Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces","volume":"44","author":"Tillman","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"10.1016\/j.ihj.2025.02.007_bib8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/ATVBAHA.113.301598","article-title":"Targeting factor XI to prevent thrombosis","volume":"33","author":"Morrissey","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ihj.2025.02.007_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.ATV.19.1.170","article-title":"Thrombin activates factor XI on activated platelets in the absence of factor XII","volume":"19","author":"Oliver","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ihj.2025.02.007_bib10","article-title":"Transient particle tracking microrheology of plasma coagulation via the intrinsic pathway","volume":"33","author":"Mao","year":"2023","journal-title":"Appl Rheol"},{"issue":"1","key":"10.1016\/j.ihj.2025.02.007_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.15872","article-title":"Advances in understanding the molecular mechanisms that maintain normal haemostasis","volume":"186","author":"O'Donnell","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ihj.2025.02.007_bib12","article-title":"Idh-1 status and venous thromboembolism in Glioma patients","volume":"1\u20135","author":"Aly","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ihj.2025.02.007_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/nrcardio.2017.171","article-title":"Discovery and purification of heparin","author":"Lim","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.ihj.2025.02.007_bib14","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jth.13555","article-title":"A century of heparin: past, present and future","volume":"14","author":"Hemker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ihj.2025.02.007_bib15","doi-asserted-by":"crossref","first-page":"243s","DOI":"10.1016\/S0223-5234(23)00128-9","article-title":"Design of potent nonpeptidic fibrinogen receptor antagonists","volume":"30","author":"Himmelsbach","year":"1995","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ihj.2025.02.007_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fphar.2013.00012","article-title":"The discovery of dabigatran etexilate","volume":"4","author":"van Ryn","year":"2013","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ihj.2025.02.007_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejmech.2016.05.039","article-title":"Contemporary developments in the discovery of selective factor Xa inhibitors: a review","volume":"121","author":"Patel","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.ihj.2025.02.007_bib18","first-page":"103","article-title":"Direct-acting oral anticoagulants and their reversal agents-an update","volume":"6","author":"Kustos","year":"2019","journal-title":"Medicines (Basel)"},{"issue":"10","key":"10.1016\/j.ihj.2025.02.007_bib19","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/cvr\/cvac091","article-title":"What to expect from drug targeting factor XI?","volume":"118","author":"Nagy","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ihj.2025.02.007_bib20","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(16)30354-1","article-title":"The hemostatic role of factor XI","volume":"141","author":"Puy","year":"2016","journal-title":"Thromb Res"},{"issue":"Suppl 2","key":"10.1016\/j.ihj.2025.02.007_bib21","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0049-3848(16)30363-2","article-title":"Factor XI and factor XII as targets for new anticoagulants","volume":"141","author":"Weitz","year":"2016","journal-title":"Thromb Res"},{"issue":"9","key":"10.1016\/j.ihj.2025.02.007_bib22","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.12998\/wjcc.v10.i9.2700","article-title":"Associations between coagulation factor XII, coagulation factor XI, and stability of venous thromboembolism: a case-control study","volume":"10","author":"Meng","year":"2022","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.ihj.2025.02.007_bib23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ihj.2025.02.007_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"Gruber","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ihj.2025.02.007_bib25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ihj.2025.02.007_bib26","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.jacc.2019.08.1027","article-title":"Are ticks the answer to medical device-associated clotting?","volume":"74","author":"Weitz","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2025.02.007_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.5551\/jat.30940","article-title":"Tissue factor and atherothrombosis","volume":"22","author":"Tatsumi","year":"2015","journal-title":"J Atherosclerosis Thromb"},{"issue":"13","key":"10.1016\/j.ihj.2025.02.007_bib28","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"David gailani; structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ihj.2025.02.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4755-2-1","article-title":"Dutch women with a low birth weight have an increased risk of myocardial infarction later in life: a case control study","volume":"2","author":"Tanis","year":"2005","journal-title":"Reprod Health"},{"key":"10.1016\/j.ihj.2025.02.007_bib30","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ihj.2025.02.007_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2025.02.007_bib32","unstructured":"Ionis Pharmaceuticals Inc. A study of ISIS 416858 administered subcutaneously to participants with end-stage renal disease (ESRD) on hemodialysis (EMERALD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03358030 (accessed on 23rd December, 2023)."},{"issue":"2","key":"10.1016\/j.ihj.2025.02.007_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2025.02.007_bib34","unstructured":"Bayer. Study to investigate the safety of a drug called osocimab at low and high doses in adult patients with kidney failure requiring regular hemodialysis (CONVERT). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04523220. (accessed 23rd December, 2023)."},{"issue":"7","key":"10.1016\/j.ihj.2025.02.007_bib35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"ANT-005 TKA investigators. Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2025.02.007_bib36","author":"Multicenter"},{"issue":"23","key":"10.1016\/j.ihj.2025.02.007_bib39","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"AXIOMATIC-TKR investigators. Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ihj.2025.02.007_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose- dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"10.1016\/j.ihj.2025.02.007_bib42","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"issue":"suppl ment_2","key":"10.1016\/j.ihj.2025.02.007_bib45","article-title":"The complete bioavailability of asundexian is unaffected by tablet formulation, gastric pH or food,","volume":"43","author":"Kanefendt","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ihj.2025.02.007_bib46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jth.15722","article-title":"Commentary on \"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa\": small molecule factor XIa inhibitor asundexian allows for safer anticoagulation","volume":"20","author":"Mailer","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"10357","key":"10.1016\/j.ihj.2025.02.007_bib47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"10333","key":"10.1016\/j.ihj.2025.02.007_bib48","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ihj.2025.02.007_bib49","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"PACIFIC AMI investigators. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2025.02.007_bib50","first-page":"100464","article-title":"OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: have we come to the end of the road for factor XIa inhibitors?","volume":"46","author":"Ferdinand","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2025.02.007_bib52","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding","volume":"118","author":"Revenko","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ihj.2025.02.007_bib53","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cts.13180","article-title":"A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab","volume":"15","author":"McKenzie","year":"2022","journal-title":"Clin Transl Sci."},{"key":"10.1016\/j.ihj.2025.02.007_bib54","first-page":"109","article-title":"Pricing of monoclonal antibody therapies: higher if used for cancer?","volume":"24","author":"Hernandez","year":"2018","journal-title":"Am J Manag Care"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483225000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483225000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T16:43:26Z","timestamp":1747759406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483225000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0019483225000422"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2025.02.007","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI and XII inhibitors\u2013Dawn of a new era","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2025.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}